Department of Clinical and Toxicology Analysis, Center of Healthy Sciences, Federal University of Santa Maria (UFSM), Santa Maria, Brazil.
Microb Pathog. 2022 Mar;164:105455. doi: 10.1016/j.micpath.2022.105455. Epub 2022 Feb 24.
The aim of this study was to investigate the clinical and oxidative profile, including the activity of the enzyme delta-aminolevulinate dehydratase (δ-ALA-D), in women who acquired toxoplasmosis during pregnancy and used the triple regimen (sulfadiazine + pyrimethamine + folinic acid [SPFA]) as treatment. These parameters have not been evaluated in pregnant women with toxoplasmosis who used the triple regimen. A total of 53 pregnant women were recruited and divided into two groups: control (C; n = 27) and acute toxoplasmosis (AT; n = 26). Clinical data and blood samples were obtained from all patients. The clinical profile was analyzed by checking parameters such as body mass index, blood pressure, and complete blood count. Oxidative stress was evaluated by quantifying protein (P-SH) and non-protein (NP-SH) thiol groups, vitamin C, plasma iron reduction capacity (FRAP), δ-ALA-D enzyme activity, reactive substances to thiobarbituric acid (TBARS), and nitric oxide (NO). Changes in hematological parameters (increased red cell distribution width and decreased hemoglobin and mean corpuscular hemoglobin concentration), increased antioxidant system (P-SH, NP-SH, FRAP, δ-ALA-D enzyme activity), as well as damage markers (TBARS and NO), were significantly elevated in pregnant women with toxoplasmosis, compared to those in the control group. Pregnant women treated for this acute infection showed increased damage markers, as well as a significant increase in the antioxidant system, including the activity of the δ-ALA-D enzyme. Given this evidence, it is suggested that these changes occur as a form of compensation, with a possible contribution from drug therapy.
本研究旨在调查患有弓形体病的孕妇（接受三联疗法：磺胺嘧啶+乙胺嘧啶+亚叶酸 [SPFA] 治疗）的临床和氧化特征，包括 δ-氨基乙酰丙酸脱水酶（δ-ALA-D）的活性。尚未评估接受三联疗法治疗的弓形体病孕妇的这些参数。共招募了 53 名孕妇，分为两组：对照组（C；n=27）和急性弓形体病组（AT；n=26）。从所有患者中采集临床数据和血液样本。通过检查体重指数、血压和全血细胞计数等参数来分析临床特征。通过定量测定蛋白质（P-SH）和非蛋白质（NP-SH）巯基、维生素 C、血浆铁还原能力（FRAP）、δ-ALA-D 酶活性、硫代巴比妥酸反应物质（TBARS）和一氧化氮（NO）来评估氧化应激。与对照组相比，患有弓形体病的孕妇的血液学参数发生变化（红细胞分布宽度增加，血红蛋白和平均红细胞血红蛋白浓度降低），抗氧化系统增加（P-SH、NP-SH、FRAP、δ-ALA-D 酶活性），以及损伤标志物（TBARS 和 NO）增加。接受这种急性感染治疗的孕妇显示出损伤标志物增加，以及抗氧化系统的显著增加，包括 δ-ALA-D 酶的活性。有鉴于此，这些变化可能是一种代偿形式，可能与药物治疗有关。
